![](/img/cover-not-exists.png)
Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer
Christodoulos Stefanadis, Andreas Synetos, Dimitris Tousoulis, Eleftherios Tsiamis, Archontoula Michelongona, Flora Zagouri, Aristotle Bamias, Meletios Athanasios Dimopoulos, Stella Kyvelou, Ioannis KVolume:
154
Year:
2012
Language:
english
DOI:
10.1016/j.ijcard.2011.10.115
File:
PDF, 161 KB
english, 2012